Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2006-4-25
pubmed:abstractText
Ximelagatran is a novel direct thrombin inhibitor that can be administered as a fixed oral dose, without the need for anticoagulant monitoring.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0003-9926
pubmed:author
pubmed:issnType
Print
pubmed:day
24
pubmed:volume
166
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
853-9
pubmed:meshHeading
pubmed-meshheading:16636210-Adolescent, pubmed-meshheading:16636210-Adult, pubmed-meshheading:16636210-Aged, pubmed-meshheading:16636210-Anticoagulants, pubmed-meshheading:16636210-Atrial Fibrillation, pubmed-meshheading:16636210-Azetidines, pubmed-meshheading:16636210-Benzylamines, pubmed-meshheading:16636210-Female, pubmed-meshheading:16636210-Follow-Up Studies, pubmed-meshheading:16636210-Hemorrhage, pubmed-meshheading:16636210-Humans, pubmed-meshheading:16636210-Incidence, pubmed-meshheading:16636210-Male, pubmed-meshheading:16636210-Middle Aged, pubmed-meshheading:16636210-Risk Factors, pubmed-meshheading:16636210-Survival Rate, pubmed-meshheading:16636210-Thrombosis, pubmed-meshheading:16636210-Time Factors, pubmed-meshheading:16636210-Treatment Outcome, pubmed-meshheading:16636210-Warfarin
pubmed:year
2006
pubmed:articleTitle
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
pubmed:affiliation
Department of Medicine, McMaster University, Hamilton, Ontario, Canada. jdouket@mcmaster.ca
pubmed:publicationType
Journal Article, Randomized Controlled Trial